ArticleMolecular psychiatry2025
Morphological alterations of the thymus gland in individuals with schizophrenia.
Article in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Despite its critical function in the immune system and accumulating evidence of immunological abnormalities in schizophrenia, the thymus has long been overlooked. We aimed to investigate thymic morphological alterations and their corresponding heterogeneity in patients with schizophrenia. Imaging-derived thymic morphology was assessed and compared between 419 patients with schizophrenia and 460 age- and sex-matched control participants aged 16-40 years who underwent chest computed tomography (CT) scanning. These included measurements reflecting thymic size and density, such as average maximal thickness, anteroposterior distance, and average CT attenuation, which were also used to identify patient subtypes based on an unsupervised machine learning algorithm. Once the thymus-based patient subtypes were identified, between-subtype differences in the thymic and blood immunometabolic profiles were further tested. Case-control comparisons revealed that patients had greater average maximal thickness (Glass's delta [Δ] effect size = 0.37) but lower average CT attenuation (Δ = -0.18) in the thymus than controls. Two thymus-based subtypes with disparate thymic and blood immunometabolic profiles were identified. Specifically, Subtype 1 (containing 40.1% of patients) was characterized as greater average maximal thickness (Δ = 1.36) and longer anteroposterior distance (Δ = 0.71) but lower CT attenuation (Δ = -0.97), contrary to the abnormal patterns of Subtype 2. Furthermore, Subtype 1 had higher levels of blood immunometabolic profiles, such as lymphocyte count and lipid measures, than Subtype 2. Altered thymic morphology with considerable heterogeneity was first reported in schizophrenia, providing evidence for the immune hypothesis and facilitating the discovery of imaging biomarkers reflecting the immunometabolic status.
Indexed as
Identifiers
40038543What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.